Monolayer Nimesulide Thiocolchicoside Tablet Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional monolayer tablets face challenges in combining nimesulide and thiocolchicoside due to physicochemical incompatibility and stability issues, which are typically addressed in trilayer tablets, but these are less economical and more complex, making them less patient-friendly.
Innovation Solution
A monolayer tablet formulation using specific particle sizes of lactose monohydrate and microcrystalline cellulose to enhance solubility and stability, reducing the need for excipients and simplifying the manufacturing process, while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If nimesulide and thiocolchicoside are combined in a monolayer tablet, then patient compliance and convenience are improved, but physicochemical compatibility and stability deteriorate
Solution Approach 1:
The patent introduces an inert layer as an intermediary barrier between nimesulide and thiocolchicoside layers. This inert layer prevents direct contact and potential chemical interactions between the two active ingredients, thereby maintaining physicochemical compatibility while allowing both drugs to be delivered in a single tablet formulation that improves patient compliance.
Solution Approach 2:
The patent divides the tablet into multiple functional layers: a nimesulide-containing layer, a thiocolchicoside-containing layer, and an inert separating layer. This segmentation allows each active ingredient to be housed in its own compartment, preventing unwanted interactions while maintaining the convenience of a single tablet regimen.
2Stability of the object's composition
If trilayer tablet is used to separate nimesulide and thiocolchicoside, then stability is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent extracts only the essential function of separation by removing the third active ingredient layer from the trilayer design. The simplified two-layer structure with an inert barrier maintains the stability benefits of separation while eliminating the manufacturing complexity associated with three-layer tablet production.
3Reliability
If more excipients are added to ensure solubility and stability, then therapeutic efficacy is maintained, but side effects and manufacturing cost increase
Solution Approach 1:
The patent optimizes the physical and chemical parameters of the excipients used, such as particle size, surface area, and surface properties of lactose and microcrystalline cellulose. By adjusting these parameters, the formulation achieves adequate solubility and stability with minimal excipient quantities, thereby reducing potential side effects and manufacturing costs while maintaining therapeutic efficacy.
Data Source
AI summary
The present invention relates to a tablet formulation comprising nimesulide, thiocolchicoside, lactose monohydrate and microcrystalline cellulose and one or more pharmaceutically acceptable excipients.